CD8A and neoplasm: Although KLRG1 is considered as an immune checkpoint marker and anti-KLRG1 antibody has been shown to prevent tumor metastasis32, it is not contradictory with our findings that these KLRG1+CD8 T cells with exhaustion phenotypes could also exert antitumor effects.